OTCMKTS:DDXSQ

Diadexus Competitors

Add

Compare

Today's Range N/A

50-Day Range N/A

52-Week Range N/A

Volume100 shs

Average Volume5,050 shs

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

Beta-3.56

Diadexus (OTCMKTS:DDXSQ) Vs. ACUS, AFFY, ARYX, AHROQ, CBPI, and CDSG

Should you be buying DDXSQ stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Diadexus, including Acusphere (ACUS), Affymax (AFFY), ARYx Therapeutics (ARYX), AtheroNova (AHROQ), China Botanic Pharmaceutical (CBPI), and China Dongsheng International (CDSG).

Diadexus vs. Acusphere Stock

Diadexus (OTCMKTS:DDXSQ) and Acusphere (OTCMKTS:ACUS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, earnings, profitability and institutional ownership.

Analyst Recommendations

This is a summary of recent ratings for Diadexus and Acusphere, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Diadexus	0	0	0	0	N/A
Acusphere	0	0	0	0	N/A

Profitability

This table compares Diadexus and Acusphere's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Diadexus	N/A	N/A	N/A
Acusphere	N/A	N/A	N/A

Valuation & Earnings

This table compares Diadexus and Acusphere's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Diadexus	N/A	N/A	N/A	N/A	N/A
Acusphere	N/A	N/A	N/A	N/A	N/A

Risk & Volatility

Diadexus has a beta of -3.56, indicating that its stock price is 456% less volatile than the S&P 500. Comparatively, Acusphere has a beta of -0.25, indicating that its stock price is 125% less volatile than the S&P 500.

Summary

Acusphere beats Diadexus on 1 of the 1 factors compared between the two stocks.

Diadexus vs. Affymax Stock

Affymax (OTCMKTS:AFFY) and Diadexus (OTCMKTS:DDXSQ) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Valuation & Earnings

This table compares Affymax and Diadexus' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Affymax	N/A	N/A	N/A	N/A	N/A
Diadexus	N/A	N/A	N/A	N/A	N/A

Profitability

This table compares Affymax and Diadexus' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Affymax	N/A	N/A	N/A
Diadexus	N/A	N/A	N/A

Volatility & Risk

Affymax has a beta of 2.77, indicating that its share price is 177% more volatile than the S&P 500. Comparatively, Diadexus has a beta of -3.56, indicating that its share price is 456% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for Affymax and Diadexus, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Affymax	0	0	0	0	N/A
Diadexus	0	0	0	0	N/A

Summary

Affymax beats Diadexus on 1 of the 1 factors compared between the two stocks.

Diadexus vs. ARYx Therapeutics Stock

Diadexus (OTCMKTS:DDXSQ) and ARYx Therapeutics (OTCMKTS:ARYX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

Profitability

This table compares Diadexus and ARYx Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Diadexus	N/A	N/A	N/A
ARYx Therapeutics	N/A	N/A	N/A

Volatility & Risk

Diadexus has a beta of -3.56, indicating that its stock price is 456% less volatile than the S&P 500. Comparatively, ARYx Therapeutics has a beta of -0.53, indicating that its stock price is 153% less volatile than the S&P 500.

Earnings & Valuation

This table compares Diadexus and ARYx Therapeutics' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Diadexus	N/A	N/A	N/A	N/A	N/A
ARYx Therapeutics	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of current ratings and target prices for Diadexus and ARYx Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Diadexus	0	0	0	0	N/A
ARYx Therapeutics	0	0	0	0	N/A

Summary

ARYx Therapeutics beats Diadexus on 1 of the 1 factors compared between the two stocks.

Diadexus vs. AtheroNova Stock

AtheroNova (OTCMKTS:AHROQ) and Diadexus (OTCMKTS:DDXSQ) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, valuation and profitability.

Analyst Ratings

This is a summary of recent ratings and recommmendations for AtheroNova and Diadexus, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AtheroNova	0	0	0	0	N/A
Diadexus	0	0	0	0	N/A

Profitability

This table compares AtheroNova and Diadexus' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AtheroNova	N/A	N/A	N/A
Diadexus	N/A	N/A	N/A

Volatility and Risk

AtheroNova has a beta of -8.71, indicating that its share price is 971% less volatile than the S&P 500. Comparatively, Diadexus has a beta of -3.56, indicating that its share price is 456% less volatile than the S&P 500.

Earnings & Valuation

This table compares AtheroNova and Diadexus' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AtheroNova	N/A	N/A	N/A	N/A	N/A
Diadexus	N/A	N/A	N/A	N/A	N/A

Summary

Diadexus beats AtheroNova on 1 of the 1 factors compared between the two stocks.

Diadexus vs. China Botanic Pharmaceutical Stock

China Botanic Pharmaceutical (OTCMKTS:CBPI) and Diadexus (OTCMKTS:DDXSQ) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, earnings, risk and analyst recommendations.

Valuation & Earnings

This table compares China Botanic Pharmaceutical and Diadexus' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China Botanic Pharmaceutical	N/A	N/A	N/A	N/A	N/A
Diadexus	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent recommendations and price targets for China Botanic Pharmaceutical and Diadexus, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China Botanic Pharmaceutical	0	0	0	0	N/A
Diadexus	0	0	0	0	N/A

Profitability

This table compares China Botanic Pharmaceutical and Diadexus' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
China Botanic Pharmaceutical	N/A	N/A	N/A
Diadexus	N/A	N/A	N/A

Risk and Volatility

China Botanic Pharmaceutical has a beta of 17.09, indicating that its stock price is 1,609% more volatile than the S&P 500. Comparatively, Diadexus has a beta of -3.56, indicating that its stock price is 456% less volatile than the S&P 500.

Summary

China Botanic Pharmaceutical beats Diadexus on 1 of the 1 factors compared between the two stocks.

Diadexus vs. China Dongsheng International Stock

China Dongsheng International (OTCMKTS:CDSG) and Diadexus (OTCMKTS:DDXSQ) are both consumer staples companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, valuation, risk, dividends and analyst recommendations.

Analyst Recommendations

This is a summary of current recommendations for China Dongsheng International and Diadexus, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China Dongsheng International	0	0	0	0	N/A
Diadexus	0	0	0	0	N/A

Earnings & Valuation

This table compares China Dongsheng International and Diadexus' top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China Dongsheng International	N/A	N/A	N/A	N/A	N/A
Diadexus	N/A	N/A	N/A	N/A	N/A

Profitability

This table compares China Dongsheng International and Diadexus' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
China Dongsheng International	N/A	N/A	N/A
Diadexus	N/A	N/A	N/A

Volatility and Risk

China Dongsheng International has a beta of 13.38, indicating that its share price is 1,238% more volatile than the S&P 500. Comparatively, Diadexus has a beta of -3.56, indicating that its share price is 456% less volatile than the S&P 500.

Summary

China Dongsheng International beats Diadexus on 1 of the 1 factors compared between the two stocks.